Biohaven is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Our product candidates are small molecules based on two distinct mechanistic platforms—calcitonin gene-related peptide, or CGRP, receptor antagonists and glutamate modulators—which we believe have the potential to significantly alter existing treatment approaches across a diverse set of neurological indications with high unmet need in both large markets and orphan indications.
Statement of Beneficial Ownership
Statement of Ownership
Biohaven's Trigriluzole Receives Fast Track Designation From U.S. FDA
Biohaven Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
View Our Board of Directors, Committees, and Governance Documents.
Access Our Investor Relations contact information to get in touch.
Receive SEC Filings, Events, News Releases and Stock Price Alerts.